Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
HER-2/neu Oncogenic Protein: Issues in Vaccine Development
RESUMO
Vaccine studies using whole tumor cells or heterogeneous mixtures of tumor antigens provide intriguing evidence that cancer vaccines might be effective. Now it is possible to test vaccines composed of well-characterized proteins and peptides. Testing vaccine formulations composed of known and defined antigens will allow a more precise determination as to why vaccines work when they work, and why they do not work when they fail. The demonstration that human malignancy is immunogenic and the definition of human tumor antigens has set the stage for a new generation of cancer vaccines directly targeting immunogenic cancer-related peptides and proteins. Many newly defined tumor antigens are self proteins. As an example, screening existent immunity in human melanoma has identified responses to nonmutated self proteins: MAGE, MART, gplOO, and tyrosinase. Tolerance to self antigens now emerges as a possible mechanism of tumor immune escape. A new puzzle has emerged for tumor immunologists to solve; how to harness immunity to "self" tumor antigens for cancer therapeutics.
-
Curigliano Giuseppe, Spitaleri Gianluca, Dettori Manuela, Locatelli Marzia, Scarano Eloise, Goldhirsch Aron, Vaccine immunotherapy in breast cancer treatment: promising, but still early, Expert Review of Anticancer Therapy, 7, 9, 2007. Crossref
-
Disis Mary L., West Howard L., Schiffman Kathy, Cancer Vaccines for the Treatment and Prevention of Non–Small-Cell Lung Cancer, Clinical Lung Cancer, 1, 4, 2000. Crossref
-
Knutson K. L., Disis M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy, Cancer Immunology, Immunotherapy, 54, 8, 2005. Crossref
-
Ben-Yedidia Tamar, Arnon Ruth, Epitope-based vaccine against influenza, Expert Review of Vaccines, 6, 6, 2007. Crossref
-
Disis Mary L, Schiffman Kathy, Salazar Lupe G, Almand Bond, Knutson Keith L, , 21, 2003. Crossref
-
Schiffman Kathy, Disis Mary L., HER2/neu Peptide-Based Vaccines, with GM-CSF as an Adjuvant, in Patients with Advanced-Stage HER2/neu–Expressing Cancers, Clinical Lung Cancer, 2, 1, 2000. Crossref
-
LATTIME EDMUND C., EISENLOHR LAURENCE C., GOMELLA LEONARD G., MASTRANGELO MICHAEL J., In Situ Immune Modulation Using Recombinant Vaccinia Virus Vectors: Preclinical Studies to Clinical Implementation, in Gene Therapy of Cancer, 2002. Crossref
-
Knutson Keith L., Disis Mary L., Expansion of HER2/neu-Specific T Cells Ex Vivo Following Immunization with a HER2/neu Peptide-Based Vaccine, Clinical Breast Cancer, 2, 1, 2001. Crossref
-
Sharma Anupama, Czerniecki Brian J, Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells, Expert Review of Clinical Pharmacology, 2, 5, 2009. Crossref
-
DeLuca D. S., Blasczyk R., The immunoinformatics of cancer immunotherapy, Tissue Antigens, 70, 4, 2007. Crossref
-
Hueman Matthew T., Stojadinovic Alexander, Storrer Catherine E., Dehqanzada Zia A., Gurney Jennifer M., Shriver Craig D., Ponniah Sathibalan, Peoples George E., Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine, Cancer Immunology, Immunotherapy, 56, 2, 2006. Crossref
-
Gordan J.D., Vonderheide R.H., Universal tumor antigens as targets for immunotherapy, Cytotherapy, 4, 4, 2002. Crossref
-
Herlyn Dorothee, Birebent Brigitte, Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development, Annals of Medicine, 31, 1, 1999. Crossref
-
Smith Heath A., McNeel Douglas G., The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy, Clinical and Developmental Immunology, 2010, 2010. Crossref
-
Klapper Leah N., Kirschbaum Mark H., Seta Michael, Yarden Yosef, , 77, 1999. Crossref
-
Eccles Suzanne, c-erbB-2 as a target for immunotherapy, Expert Opinion on Investigational Drugs, 7, 11, 1998. Crossref
-
HANSKI CHRISTOPH, ITZKOWITZ STEVEN H., Translating the Knowledge of Molecular Alterations That Occur during Colon Carcinogenesis into Clinically Relevant Solutions, Annals of the New York Academy of Sciences, 910, 1, 2006. Crossref
-
Muller Claude P., Putz Mike M., Peptide Vaccines, in Topley & Wilson's Microbiology and Microbial Infections, 2010. Crossref
-
Knutson Keith L., Schiffman Kathy, Disis Mary L., Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients, Journal of Clinical Investigation, 107, 4, 2001. Crossref
-
Miyamoto Hiroshi, Kubota Yoshinobu, Noguchi Sumio, Takase Kazunori, Matsuzaki Junichi, Moriyama Masatoshi, Takebayashi Shigeo, Kitamura Hitoshi, Hosaka Masahiko, c-erbb-2 gene amplification as a prognostic marker in human bladder cancer, Urology, 55, 5, 2000. Crossref
-
Pietersz Geoffrey A, Li Wenjun, Apostolopoulos Vasso, A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway, Vaccine, 19, 11-12, 2001. Crossref
-
Mittendorf Elizabeth A, Holmes Jarrod P, Murray James L, von Hofe Eric, Peoples George E, CD4+T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37), Expert Opinion on Biological Therapy, 9, 1, 2009. Crossref
-
Kiessling Rolf, Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., Seliger B., , 85, 2002. Crossref
-
Havranek E.G., Whelan M.A., Greenhalgh R., Dalgleish A.G., Pandha H., Advances in prostate cancer immunotherapy, Surgical Oncology, 11, 1-2, 2002. Crossref
-
Cruz Jay S.Dela, Lau Suk Ying, Ramirez Ernesto M, Giovanni Carla De, Forni Guido, Morrison Sherie L, Penichet Manuel L, Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice, Vaccine, 21, 13-14, 2003. Crossref
-
Salazar Lupe G., Coveler Andrew L., Swensen Ron E., Gooley Theodore A., Goodell Vivian, Schiffman Kathy, Disis Mary L., Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers, Clinical Immunology, 125, 3, 2007. Crossref
-
Hudson Amy R., Smoller Bruce R., IMMUNOHISTOCHEMISTRY IN DIAGNOSTIC DERMATOPATHOLOGY, Dermatologic Clinics, 17, 3, 1999. Crossref
-
Fioretti Daniela, Iurescia Sandra, Fazio Vito Michele, Rinaldi Monica, DNA Vaccines: Developing New Strategies against Cancer, Journal of Biomedicine and Biotechnology, 2010, 2010. Crossref
-
Salgaller Michael L, The development of immunotherapies for non-small cell lung cancer, Expert Opinion on Biological Therapy, 2, 3, 2002. Crossref
-
Pejawar-Gaddy Sharmila, Finn Olivera J., Cancer vaccines: Accomplishments and challenges, Critical Reviews in Oncology/Hematology, 67, 2, 2008. Crossref
-
Vlahopoulos Spiros, Gritzapis Angelo D., Perez Sonia A., Cacoullos Nike, Papamichail Michail, Baxevanis Constantine N., Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin, Vaccine, 27, 34, 2009. Crossref
-
Kao Henry , Marto Jarrod A. , Hoffmann Thomas K. , Shabanowitz Jeffrey , Finkelstein Sydney D. , Whiteside Theresa L. , Hunt Donald F. , Finn Olivera J. , Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , Journal of Experimental Medicine, 194, 9, 2001. Crossref
-
Kono Koji, Takahashi Akihiro, Amemiya Hideki, Ichihara Fumiko, Sugai Hidemitsu, Iizuka Hidehiko, Fujii Hideki, Matsumoto Yoshiro, Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer, International Journal of Cancer, 98, 2, 2002. Crossref
-
Bell Richard, Duration of therapy in metastatic breast cancer: management using Herceptin®, Anti-Cancer Drugs, 12, 7, 2001. Crossref
-
Villunger Andreas, Strasser Andreas, The great escape: Is immune evasion required for tumor progression?, Nature Medicine, 5, 8, 1999. Crossref
-
Vidovic Damir, Graddis Thomas, Chen Feng, Slagle Paul, Diegel Michael, Stepan Lara, Laus Reiner, Antitumor vaccination with HER-2-derived recombinant antigens, International Journal of Cancer, 102, 6, 2002. Crossref
-
Graziano Daniel F., Finn Olivera J., Tumor Antigens and Tumor Antigen Discovery, in Tumor Immunology and Cancer Vaccines, 123, 2005. Crossref
-
Nicchitta Christopher V., gp96 and Tumor Immunity, in Cell Stress Proteins, 7, 2007. Crossref
-
Meyer zum Büschenfelde Christian, Metzger Jochen, Hermann Christine, Nicklisch Nicole, Peschel Christian, Bernhard Helga, The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells, The Journal of Immunology, 167, 3, 2001. Crossref
-
Meyer zum Büschenfelde Christian, Nicklisch Nicole, Rose-John Stefan, Peschel Christian, Bernhard Helga, Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+Hemopoietic Progenitor Cells, The Journal of Immunology, 165, 7, 2000. Crossref
-
Ying Han, Zeng Gang, Black Keith L., Innovative Cancer Vaccine Strategies Based on the Identification of Tumour-Associated Antigens, BioDrugs, 15, 12, 2001. Crossref
-
Berger Carmen M., Knutson Keith L., Salazar Lupe G., Kathy Schiffman PA-C, Disis Mary L., Peptide-Based Vaccines, in Handbook of Cancer Vaccines, 2004. Crossref
-
McNeel Douglas G., Schiffman Kathy, Disis Mary L., Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 93, 8, 1999. Crossref
-
McNeel Douglas G., Schiffman Kathy, Disis Mary L., Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 93, 8, 1999. Crossref
-
Ghahremanifard Parisa, Afzali Farzaneh, Rostami Amin, Nayeri Zahra, Bambai Bijan, Minuchehr Zarrin, Designing a Novel Multi-epitope T Vaccine for “Targeting Protein for Xklp-2” (TPX2) in Hepatocellular Carcinoma Based on Immunoinformatics Approach, International Journal of Peptide Research and Therapeutics, 26, 2, 2020. Crossref
-
Disis Mary L., Rinn Kristine, Knutson Keith L., Davis Donna, Caron Dania, dela Rosa Corazon, Schiffman Kathy, Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers, Blood, 99, 8, 2002. Crossref
-
Baxevanis Constantin N, Voutsas Ioannis F, Gritzapis Angelos D, Perez Sonia A, Papamichail Michael, HER-2/neu as a target for cancer vaccines, Immunotherapy, 2, 2, 2010. Crossref
-
Janikashvili Nona, Larmonier Nicolas, Katsanis Emmanuel, Personalized dendritic cell-based tumor immunotherapy, Immunotherapy, 2, 1, 2010. Crossref
-
Disis Mary L., Gooley Theodore A., Rinn Kristine, Davis Donna, Piepkorn Michael, Cheever Martin A., Knutson Keith L., Schiffman Kathy, Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines, Journal of Clinical Oncology, 20, 11, 2002. Crossref
-
Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M, Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma, Gene Therapy, 12, 17, 2005. Crossref
-
Lane Cecilia, Leitch Jaina, Tan Xiaohua, Hadjati Jamishid, Bramson Jonathan L., Wan Yonghong, Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin, Cancer Research, 64, 4, 2004. Crossref
-
Houghton Raymond L., Dillon Davin C., Molesh David A., Zehentner Barbara K., Xu Jiangchun, Jiang John, Schmidt Cheryl, Frudakis Anthony, Repasky Elizabeth, Filho Aristides Maltez, Nolasco Marcos, Badaro Roberto, Zhang Xinqun, Roche Patrick C., Persing David H., Reed Steven G., Transcriptional Complementarity in Breast Cancer: Application to Detection of Circulating Tumor Cells, Molecular Diagnosis, 6, 2, 2001. Crossref